Novo Nordisk Total Long Term Liabilities 2010-2024 | NVO

Novo Nordisk total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • Novo Nordisk total long term liabilities for the quarter ending September 30, 2024 were $10.106B, a 100.3% increase year-over-year.
  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
  • Novo Nordisk total long term liabilities for 2021 were $3.858B, a 122.36% increase from 2020.
Novo Nordisk Annual Total Long Term Liabilities
(Millions of US $)
2023 $5,557
2022 $5,215
2021 $3,858
2020 $1,735
2019 $1,354
2018 $729
2017 $833
2016 $718
2015 $589
2014 $549
2013 $631
2012 $587
2011 $1,209
2010 $1,063
2009 $1,048
Novo Nordisk Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $10,106
2024-06-30 $9,950
2024-03-31 $5,009
2023-12-31 $5,557
2023-09-30 $5,045
2023-06-30 $4,918
2023-03-31 $5,503
2022-12-31 $5,215
2022-09-30 $4,857
2022-06-30 $4,979
2022-03-31 $5,276
2021-12-31 $3,858
2021-09-30 $3,116
2021-06-30 $3,200
2021-03-31 $1,703
2020-12-31 $1,735
2020-09-30 $1,480
2020-06-30 $1,297
2020-03-31 $1,281
2019-12-31 $1,354
2019-09-30 $1,321
2019-06-30 $1,239
2019-03-31 $1,226
2018-12-31 $729
2018-09-30 $773
2018-06-30 $799
2018-03-31 $851
2017-12-31 $833
2017-09-30 $919
2017-06-30 $823
2017-03-31 $718
2016-12-31 $718
2016-09-30 $663
2016-06-30 $631
2016-03-31 $593
2015-12-31 $589
2015-09-30 $531
2015-06-30 $535
2015-03-31 $509
2014-12-31 $549
2014-09-30 $585
2014-06-30 $601
2014-03-31 $599
2013-12-31 $631
2013-09-30 $595
2013-06-30 $615
2013-03-31 $535
2012-12-31 $587
2012-09-30 $796
2012-06-30 $1,001
2012-03-31 $1,209
2011-12-31 $1,209
2011-09-30 $1,184
2011-06-30 $1,151
2011-03-31 $1,097
2010-12-31 $1,063
2010-09-30 $1,033
2010-06-30 $876
2010-03-31 $1,064
2009-12-31 $1,048
2009-09-30 $918
2009-06-30 $857
2009-03-31 $826
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51